What are investors’ and analysts’ reflections on current vibrant market sentiment and associated VC/IPO activity, and their expectations for future financing trends in the I-O space? And what is their message for industry decision-makers?
How will the market evaluate larger (but crowded) indications vs niche indications for I-O agents moving forward?
What are the implications for patients, clinicians, regulators, and the field as a whole of recent I-O product withdrawals following conditional approvals?
Mounting competition in the PD-1/PD-L1 arena: what will be the repercussions for:
Checkpoint inhibitor pricing and reimbursement? (Will we see a price war? What does that mean for the I-O industry, if so?)
When will we see the first PD-1 biosimilar? What will be its expected impact?
Combination therapy development strategy across the I-O sector?
What novel/innovative pricing and reimbursement models are best suited to next-generation I-O therapeutics, particularly as they move into earlier lines of therapy? (Eg. pay by performance models)
How can the community as a whole work to increase patient access to I-O therapeutics on a global basis?
What are the key enabling technologies enhancing novel target identification and validation for antibody therapeutics and cellular immunotherapies? Exploring their capabilities and considerations for practical application
What tools can assist in targeting tumor-associated antigens? (Eg. MHC, peptide recognition)
Evaluating cellular immunotherapies (CAR T, TCR, NK, etc.) and bimultispecific antibody therapies in solid tumor indications
Optimal approaches to improve specificity (eg. enhancing bispecific antibody avidity)
Which novel targets and pathways are showing promise in improving response rates, efficacy?
Understanding mechanisms of resistance (eg. to CAR T cell therapy in melanoma)
Targeting multiple antigens
What are the next steps towards personalizing immuno-oncology therapy to the individual TME?
What progress with approaches to break up the tumor stroma, thus enabling penetration of TILs and other therapeutics?
Assessing the current state of play and identifying next steps in terms of discovering and developing reliable markers of response in solid tumors
What new directions in biomarker discovery can novel and emerging I-O agents open up for the field (eg. LAG-3, cellular immunotherapies)?
What do resistance markers tell us about how to harness the innate immune system moving forward?
Exploring the cutting edge in imaging tools and their application in I-O (eg. PET-based tracer studies to monitor immune response; leveraging early imaging predictors to gain an idea of response; delivering noninvasive markers of disease)
What are the next steps for the field in capitalizing on the potential of single cell sequencing and analysis tools?
Mass cytometry for simultaneous multiple marker analysis
Harnessing CyTOF (cytometry by time of flight) in combination with spatial imaging
Applying AI and machine learning to integrate biomarker data (eg. with longitudinal patient data) – what is practical both now and in the future?
Evaluating the potential of circulating plasma exosomes
What is the latest thinking in terms of the role of the microbiome and its impact on immune response?
Who will fund and drive the high-risk/high-reward novel biomarker research required by the I-O field moving forward?
How and where are next-gen sequencing and analytical tools being effectively applied to improve predictability of safety and efficacy in the combination setting?
Reviewing combination therapy considerations and challenges, and defining next steps, for:
How to alleviate heightened toxicity risk for T cell redirection agents in combination?
Which tools are delivering insights into optimal combinations for CAR T cell and other cellular immunotherapies?
What are optimal pre-conditioning regimens in the solid tumor setting?
Exploring the logic of combining innate and adaptive immune system approaches
What can the latest clinical outcomes from regimens combining anti-PD-1 antibodies with intra-lesional therapies (TLR, STING, oncolytic viruses) tell us about their ability to impact distant disease sites?